IDEAS home Printed from https://ideas.repec.org/p/hal/journl/hal-04584651.html
   My bibliography  Save this paper

Edoxaban for stroke prevention in atrial fibrillation and age-adjusted predictors of clinical outcomes in routine clinical care

Author

Listed:
  • Paulus Kirchhof

    (University Hospital Hamburg-Eppendorf - UKE - Universitaetsklinikum Hamburg-Eppendorf = University Medical Center Hamburg-Eppendorf [Hamburg], DZHK - German Center for Cardiovascular Research - BIH - Berlin Institute of Health, ICAN - Unité de Recherche sur les Maladies Cardiovasculaires, du Métabolisme et de la Nutrition = Research Unit on Cardiovascular and Metabolic Diseases - AP-HP - Assistance publique - Hôpitaux de Paris (AP-HP) - INSERM - Institut National de la Santé et de la Recherche Médicale - SU - Sorbonne Université - IHU ICAN - Institut de Cardiométabolisme et Nutrition = Institute of Cardiometabolism and Nutrition [CHU Pitié Salpêtrière] - CHU Pitié-Salpêtrière [AP-HP] - AP-HP - Assistance publique - Hôpitaux de Paris (AP-HP) - SU - Sorbonne Université)

  • L. Pecen

    (The Czech Academy of Sciences, Institute of Computer Science)

  • Ameet Bakhai

    (Royal Free London NHS Foundation Trust)

  • Carlo de Asmundis
  • Joris R. de Groot

    (Department of Experimental Cardiology, Amsterdam University Medical Center - UvA - University of Amsterdam [Amsterdam] = Universiteit van Amsterdam)

  • Jean-Claude Deharo

    (Service de cardiologie - Université de la Méditerranée - Aix-Marseille 2 - APHM - Assistance Publique - Hôpitaux de Marseille - TIMONE - Hôpital de la Timone [CHU - APHM], Département de Cardiologie [Hôpital de la Timone - APHM] - APHM - Assistance Publique - Hôpitaux de Marseille - TIMONE - Hôpital de la Timone [CHU - APHM])

  • Peter Kelly

    (The Mater Hospital - Mater Misericordiae University Hospital)

  • Pierre Lévy

    (Legos - Laboratoire d'Economie et de Gestion des Organisations de Santé - Université Paris Dauphine-PSL - PSL - Université Paris Sciences et Lettres, LEDa - Laboratoire d'Economie de Dauphine - IRD - Institut de Recherche pour le Développement - Université Paris Dauphine-PSL - PSL - Université Paris Sciences et Lettres - CNRS - Centre National de la Recherche Scientifique)

  • Esteban López-De-Sá

    (Hospital La Paz Institute for Health Research (IdiPAZ), CIBERER U-754, Madrid)

  • Pedro Monteiro

    (CHUC - Coimbra Hospital and Universitary Centre [Coimbra, Portugal])

  • Jan Steffel
  • Johannes Waltenberger

    (SyNergy - Munich Cluster for systems neurology [Munich] - TUM - Technische Universität Munchen - Technical University Munich - Université Technique de Munich - LMU - Ludwig Maximilian University [Munich] = Ludwig Maximilians Universität München)

  • Thomas W. Weiss
  • Petra Laeis

    (Daiichi Sankyo Co.)

  • M. C. Manu

    (Daiichi Sankyo Co.)

  • J. Souza

    (Daiichi Sankyo Co.)

  • Raffaele De Caterina

Abstract

Aims: Patients with atrial fibrillation (AF) treated with oral anticoagulation still suffer from cardiovascular complications including cardiovascular death, stroke, and major bleeding. To identify risk factors for predicting stroke and bleeding outcomes in anticoagulated patients, we assessed 2-year outcomes in patients with AF treated with edoxaban in routine care. We also report the age-adjusted risk predictors of clinical outcomes.Methods and results: The Edoxaban Treatment in Routine Clinical Practice for Patients With Non-Valvular Atrial Fibrillation (ETNA-AF) Europe (NCT02944019) is a prospective, multi-centre, post-authorisation, observational study with an overall 4-year follow-up conducted in 825 centres enrolling edoxaban-treated patients in 10 European countries. Of the 13 133 patients with AF (mean age: 73.6 ± 9.5 years), 5682 (43.3%) were female. At the 2-year follow-up, 9017/13 133 patients were still on edoxaban; 1830 discontinued treatment including 937 who died (annualised event rate of all-cause death was 3.87%). 518 (2.14%) patients died of cardiovascular causes; 234 (0.97%) experienced major bleeding and 168 (0.70%) experienced stroke or systemic embolic events (SEE). Intracranial haemorrhage was noted in 49 patients (0.20%). History of transient ischaemic attack (TIA) at baseline was the strongest predictor of ischaemic stroke or SEE (Wald χ2: 73.63; P

Suggested Citation

  • Paulus Kirchhof & L. Pecen & Ameet Bakhai & Carlo de Asmundis & Joris R. de Groot & Jean-Claude Deharo & Peter Kelly & Pierre Lévy & Esteban López-De-Sá & Pedro Monteiro & Jan Steffel & Johannes Walte, 2022. "Edoxaban for stroke prevention in atrial fibrillation and age-adjusted predictors of clinical outcomes in routine clinical care," Post-Print hal-04584651, HAL.
    • Handle: RePEc:hal:journl:hal-04584651
    as

    Download full text from publisher

    To our knowledge, this item is not available for download. To find whether it is available, there are three options:
    1. Check below whether another version of this item is available online.
    2. Check on the provider's web page whether it is in fact available.
    3. Perform a search for a similarly titled item that would be available.

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:hal:journl:hal-04584651. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    We have no bibliographic references for this item. You can help adding them by using this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: CCSD (email available below). General contact details of provider: https://hal.archives-ouvertes.fr/ .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.